ABEO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Abeona Therapeutics Inc. (ABEO) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock lacks significant positive catalysts, has no strong trading signals, and shows limited upside potential in the short term. While the company's financials have improved, the conservative launch trajectory and lack of recent news or influential trading activity do not support a compelling buy case.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is in the neutral zone at 76.835, and moving averages are converging, suggesting no clear trend. The stock is trading near resistance levels (R1: 5.353, R2: 5.576), which could limit immediate upside potential.
Improved financial performance in 2025/Q4, with net income increasing by 120.17% YoY and EPS improving by 94.74% YoY. Gross margin remains strong at 80.74%.
Analyst price target was lowered from $27.50 to $20 due to a more conservative launch trajectory for Zevaskyn. No significant news, insider trading, hedge fund activity, or congress trading data in recent months. The stock has a 70% chance of declining in the next week and month.
In 2025/Q4, revenue remained flat YoY at $5.42M. Net income improved significantly to -$20.46M (up 120.17% YoY), and EPS increased to -0.37 (up 94.74% YoY). Gross margin was stable at 80.74%.
Alliance Global maintains a Buy rating but lowered the price target to $20 from $27.50, citing a more conservative launch trajectory for Zevaskyn.
